TORL-3-600 / TORL Biotherap - LARVOL DELTA

A novel bispecific antibody-drug conjugate targeting CEACAM5 and CDH17 exhibits potent anti-tumor activity and enhanced tumor-selectivity (AACR 2026) - "The cell binding and internalization activities of the bsAb were compared to a panel of monoclonal antibodies, including M9140 analog (an anti-CEACAM5 monoclonal antibody) and TORL-3-600 analog (an anti-CDH17 monoclonal antibody), using multiple colorectal and pancreatic cancer cell lines, The bsAb was conjugated to various topoisomerase I inhibitor payloads to generate several bispecific ADC molecules (bsADCs). Furthermore, the candidate exhibited favorable stability in human/cynomolgus plasma and good pharmacokinetic profile and tolerability in SD rats and cynomolgus monkeys. Taken together, these data support further development and broad utility of this bsADC for GI cancer treatment."

ADC • Bispecific • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH17 • CEACAM5

GS24-B025, a novel CDH17- and CEA-directed bispecific antibody-drug conjugate, for the treatment of colorectal cancer (AACR 2026) - "These data suggest the potential of GS24-B025 as an effective treatment option for CRC patients and support its further evaluation in IND-enabling studies."

ADC • Bispecific • Colorectal Cancer • Oncology • Solid Tumor • CDH17 • CEACAM5

GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), for the treatment of colorectal cancer (AACR-NCI-EORTC 2025) - "These preclinical data suggest the potential of GS24-B025 as an effective treatment option for CRC patients and support its further evaluation in IND-enabling studies."

Colorectal Cancer • Oncology • Solid Tumor • CDH17 • CEACAM5

First in Human Study of TORL-3-600 in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=70 | Active, not recruiting | Sponsor: TORL Biotherapeutics, LLC | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2025 ➔ Jun 2026

Enrollment closed • First-in-human • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline (PRNewswire) - "Proceeds from this Series B-2 financing will be used to continue the clinical development of TORL-1-23, the Company's first-in-class ADC to treat CLDN 6+ tumors, through Phase 1 and a pivotal Phase 2 trial that will start in the second half of 2024....Proceeds will also be used to fund the on-going Phase 1 studies for the TORL-2-307 program, both a monoclonal antibody (mAb) and an ADC, for the treatment of CLDN 18.2+ solid tumors, TORL-3-600, an ADC for the treatment of CDH17+ colorectal cancer, and TORL-4-500, an ADC for the treatment of Delta like non-canonical Notch Ligand 1 (DLK1) positive solid tumors."

Financing • New P1 trial • New P2 trial • Colorectal Cancer • Gastroesophageal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor